PGGM Investments Sells 1,671,035 Shares of Healthpeak Properties, Inc. $DOC

PGGM Investments lowered its stake in Healthpeak Properties, Inc. (NYSE:DOC) by 22.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,703,693 shares of the real estate investment trust’s stock after selling 1,671,035 shares during the quarter. PGGM Investments’ holdings in Healthpeak Properties were worth $91,715,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. State Street Corp lifted its holdings in shares of Healthpeak Properties by 1.8% in the third quarter. State Street Corp now owns 49,498,109 shares of the real estate investment trust’s stock worth $947,889,000 after acquiring an additional 895,460 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Healthpeak Properties by 41.0% in the third quarter. JPMorgan Chase & Co. now owns 28,236,534 shares of the real estate investment trust’s stock worth $540,730,000 after acquiring an additional 8,212,504 shares during the last quarter. Cullen Capital Management LLC lifted its holdings in shares of Healthpeak Properties by 6.7% in the third quarter. Cullen Capital Management LLC now owns 10,232,875 shares of the real estate investment trust’s stock worth $195,960,000 after acquiring an additional 641,771 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Healthpeak Properties by 4.1% in the third quarter. Dimensional Fund Advisors LP now owns 10,228,560 shares of the real estate investment trust’s stock worth $195,873,000 after acquiring an additional 400,900 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Healthpeak Properties by 28.5% in the third quarter. Bank of America Corp DE now owns 9,936,934 shares of the real estate investment trust’s stock valued at $190,292,000 after buying an additional 2,206,222 shares during the period. Institutional investors own 93.57% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on DOC shares. Argus downgraded Healthpeak Properties from a “buy” rating to a “hold” rating in a research note on Thursday, February 5th. Evercore downgraded Healthpeak Properties from an “outperform” rating to an “in-line” rating and set a $21.00 price objective for the company. in a research note on Monday, May 11th. Wall Street Zen raised Healthpeak Properties from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Morgan Stanley upped their price objective on Healthpeak Properties from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday. Finally, Scotiabank raised Healthpeak Properties to a “hold” rating in a research note on Thursday, April 23rd. Five research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $19.08.

Healthpeak Properties Stock Performance

Healthpeak Properties stock opened at $19.74 on Tuesday. The business has a 50 day moving average of $17.55 and a 200-day moving average of $17.27. Healthpeak Properties, Inc. has a 1 year low of $15.70 and a 1 year high of $19.91. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.96 and a quick ratio of 2.96. The company has a market capitalization of $13.61 billion, a P/E ratio of 61.68, a P/E/G ratio of 2.51 and a beta of 1.00.

Healthpeak Properties (NYSE:DOC) last released its earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. The business had revenue of $752.95 million during the quarter, compared to the consensus estimate of $694.59 million. Healthpeak Properties had a net margin of 7.73% and a return on equity of 2.61%. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.46 EPS. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. On average, equities research analysts predict that Healthpeak Properties, Inc. will post 1.75 earnings per share for the current year.

Healthpeak Properties Announces Dividend

The company also recently announced a monthly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 15th will be given a dividend of $0.1017 per share. This represents a c) dividend on an annualized basis and a yield of 6.2%. The ex-dividend date of this dividend is Monday, June 15th. Healthpeak Properties’s dividend payout ratio is currently 381.25%.

Insiders Place Their Bets

In other Healthpeak Properties news, insider Scott R. Bohn sold 10,989 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $19.45, for a total transaction of $213,736.05. Following the completion of the sale, the insider owned 7,636 shares of the company’s stock, valued at approximately $148,520.20. This represents a 59.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.23% of the company’s stock.

Healthpeak Properties Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.